mixed dyslipidemia Clinical Trials

7 recruitingLast updated: July 25, 2026

There are 7 actively recruiting mixed dyslipidemia clinical trials across 8 countries. Studies span Phase 3, Phase 1. Top locations include Seoul, South Korea, Acquaviva delle Fonti, Italy, Ahaus, Germany. Updated daily from ClinicalTrials.gov.


mixed dyslipidemia Trials at a Glance

7 actively recruiting trials for mixed dyslipidemia are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Phase 3 with 3 trials, with the heaviest enrollment activity in Seoul, Acquaviva delle Fonti, and Ahaus. Lead sponsors running mixed dyslipidemia studies include Addpharma Inc., A. Menarini International Licensing S.A., and Boryung Pharmaceutical Co., Ltd.

Browse mixed dyslipidemia trials by phase

Treatments under study

About mixed dyslipidemia Clinical Trials

Looking for clinical trials for mixed dyslipidemia? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new mixed dyslipidemia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about mixed dyslipidemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting

A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

mixed dyslipidemiaPrimary Hypercholesterolemiia
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company2,000 enrolled163 locationsNCT06686615
Recruiting
Phase 3

Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days

Hypercholesterolaemiamixed dyslipidemia
A. Menarini International Licensing S.A.426 enrolled1 locationNCT07614958
Recruiting

Leqvio rPMS (Regulatory Post-Marketing Surveillance in Korea)

Primary Hypercholesterolemia or Mixed Dyslipidemia
Novartis Pharmaceuticals1,500 enrolled4 locationsNCT06770543
Recruiting

A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib

Primary hypercholesterolemiamixed dyslipidemia
Boryung Pharmaceutical Co., Ltd8,606 enrolled1 locationNCT06314919
Recruiting
Phase 1

A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A

mixed dyslipidemia
Addpharma Inc.48 enrolled1 locationNCT06932705
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of AD-218

mixed dyslipidemia
Addpharma Inc.520 enrolled1 locationNCT05400317
Recruiting
Phase 3

Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed Dyslipidemia

Primary Hypercholesterolaemia and Mixed Dyslipidemia
Shanghai Junshi Bioscience Co., Ltd.582 enrolled1 locationNCT05621070